Use of ctDNA in early breast cancer: analytical validity and clinical potential.

IF 6.5 2区医学 Q1 ONCOLOGY

NPJ Breast Cancer Pub Date : 2024-06-19 DOI:10.1038/s41523-024-00653-3

François Panet, Andri Papakonstantinou, Maria Borrell, Joan Vivancos, Ana Vivancos, Mafalda Oliveira

{"title":"Use of ctDNA in early breast cancer: analytical validity and clinical potential.","authors":"François Panet, Andri Papakonstantinou, Maria Borrell, Joan Vivancos, Ana Vivancos, Mafalda Oliveira","doi":"10.1038/s41523-024-00653-3","DOIUrl":null,"url":null,"abstract":"<p><p>Circulating free tumor DNA (ctDNA) analysis is gaining popularity in precision oncology, particularly in metastatic breast cancer, as it provides non-invasive, real-time tumor information to complement tissue biopsies, allowing for tailored treatment strategies and improved patient selection in clinical trials. Its use in early breast cancer has been limited so far, due to the relatively low sensitivity of available techniques in a setting characterized by lower levels of ctDNA shedding. However, advances in sequencing and bioinformatics, as well as the use of methylome profiles, have led to an increasing interest in the application of ctDNA analysis in early breast cancer, from screening to curative treatment evaluation and minimal residual disease (MRD) detection. With multiple prospective clinical trials in this setting, ctDNA evaluation may become useful in clinical practice. This article reviews the data regarding the analytical validity of the currently available tests for ctDNA detection and the clinical potential of ctDNA analysis in early breast cancer.</p>","PeriodicalId":19247,"journal":{"name":"NPJ Breast Cancer","volume":"10 1","pages":"50"},"PeriodicalIF":6.5000,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11187121/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NPJ Breast Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41523-024-00653-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Circulating free tumor DNA (ctDNA) analysis is gaining popularity in precision oncology, particularly in metastatic breast cancer, as it provides non-invasive, real-time tumor information to complement tissue biopsies, allowing for tailored treatment strategies and improved patient selection in clinical trials. Its use in early breast cancer has been limited so far, due to the relatively low sensitivity of available techniques in a setting characterized by lower levels of ctDNA shedding. However, advances in sequencing and bioinformatics, as well as the use of methylome profiles, have led to an increasing interest in the application of ctDNA analysis in early breast cancer, from screening to curative treatment evaluation and minimal residual disease (MRD) detection. With multiple prospective clinical trials in this setting, ctDNA evaluation may become useful in clinical practice. This article reviews the data regarding the analytical validity of the currently available tests for ctDNA detection and the clinical potential of ctDNA analysis in early breast cancer.

Abstract Image

查看原文本刊更多论文

ctDNA在早期乳腺癌中的应用：分析有效性和临床潜力。

循环游离肿瘤 DNA（ctDNA）分析在精准肿瘤学中越来越受欢迎，尤其是在转移性乳腺癌中，因为它能提供无创、实时的肿瘤信息，补充组织活检的不足，从而为临床试验量身定制治疗策略并改进患者选择。由于现有技术在ctDNA脱落水平较低的情况下灵敏度相对较低，因此迄今为止在早期乳腺癌中的应用还很有限。然而，测序和生物信息学的进步以及甲基组图谱的使用，使人们越来越关注ctDNA分析在早期乳腺癌中的应用，从筛查到治愈性治疗评估和最小残留病（MRD）检测。随着多项前瞻性临床试验在该领域的开展，ctDNA 评估可能会在临床实践中发挥作用。本文回顾了目前可用的ctDNA检测试剂盒的分析有效性数据以及ctDNA分析在早期乳腺癌中的临床应用潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Breast Cancer Medicine-Pharmacology (medical)

CiteScore

10.10

自引率

1.70%

发文量

122

审稿时长

9 weeks

期刊介绍： npj Breast Cancer publishes original research articles, reviews, brief correspondence, meeting reports, editorial summaries and hypothesis generating observations which could be unexplained or preliminary findings from experiments, novel ideas, or the framing of new questions that need to be solved. Featured topics of the journal include imaging, immunotherapy, molecular classification of disease, mechanism-based therapies largely targeting signal transduction pathways, carcinogenesis including hereditary susceptibility and molecular epidemiology, survivorship issues including long-term toxicities of treatment and secondary neoplasm occurrence, the biophysics of cancer, mechanisms of metastasis and their perturbation, and studies of the tumor microenvironment.